Aardvark Therapeutics, Inc. (AARD) SEC filings

AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30

$1.33−0.19 (-12.50%)

Close on Nov 13, 2026Market cap $29.11MP/E –Yield –

SEC filings

35 of Aardvark Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 13, 2026	Nov 13, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 13, 2026	SEC EDGAR
Current report	8-K	Oct 23, 2026	Oct 23, 2026	SEC EDGAR
Current report	8-K	Oct 22, 2026	Oct 22, 2026	SEC EDGAR
Current report	8-K	Oct 6, 2026	Oct 8, 2026	SEC EDGAR
Current report	8-K	Aug 14, 2026	Aug 17, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 11, 2026	SEC EDGAR
Current report	8-K	Aug 11, 2026	Aug 11, 2026	SEC EDGAR
Proxy statement	DEF 14A	Aug 14, 2026	Jul 10, 2026	SEC EDGAR
Current report	8-K	Jun 10, 2026	Jun 12, 2026	SEC EDGAR
Current report	8-K	May 14, 2026	May 14, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	Mar 23, 2026	Mar 24, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 23, 2026	SEC EDGAR
Current report	8-K	Mar 23, 2026	Mar 23, 2026	SEC EDGAR
Current report	8-K	Feb 27, 2026	Feb 27, 2026	SEC EDGAR
Current report	8-K	Feb 9, 2026	Feb 12, 2026	SEC EDGAR
Current report	8-K	Feb 10, 2026	Feb 10, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Dec 10, 2025	Dec 10, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Nov 5, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 4, 2025	Nov 4, 2025	SEC EDGAR
Current report	8-K	Oct 8, 2025	Oct 9, 2025	SEC EDGAR
Current report	8-K	Sep 2, 2025	Sep 3, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Aug 13, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 12, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 14, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 31, 2025	SEC EDGAR
Current report	8-K	Mar 31, 2025	Mar 31, 2025	SEC EDGAR
Current report	8-K	Feb 14, 2025	Feb 14, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Aardvark Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AARD.

Compare: AARD vs VKTX · AARD vs ARTL · AARD vs GPCR · AARD vs VTVT · AARD vs BLTE

Company	Revenue	Growth
VTVT	$36.84M	+216600.0%
AARD	$0	–
VKTX	$0	–
ARTL	–	–
GPCR	–	–
BLTE	–	–

Company

Next earnings (est.): Mar 22, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 40
Held by institutions: 43.6%
Auditor: BDO USA, P.C
SEC CIK: 1774857

Advertisement
300 × 250

See a number that looks wrong?